Aspen increases revenue 16% to R41.2 bn
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced pleasing results for the year ended 30 June
Partnering with the South African Department of Health to Enhance Public Healthcare
One of Aspen’s key business imperatives is the creation of stakeholder value. The communities Aspen operates within remain amongst the Group’s most important stakeholders, with
Aspen cleared of alleged anti-competitive behavior by DA
Durban – JSE Limited-listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has welcomed the statement issued by the Democratic Alliance (“DA”)
Aspen concludes strategic M.O.U with the Russian Federation
Windhoek, Namibia – JSE Limited listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has announced that a memorandum of understanding (“M.O.U”)
Statement in response to The Times of London report on 20 May 2017 on Florinef
Having noted the report published in The Times of London on 20 May 2017 titled “Massive price rise for vital drug put pets’ lives at
Opening of European Commission proceedings
Aspen confirms that the European Commission has opened proceedings to investigate certain actions of Aspen Holdings and certain of its European subsidiaries. While Aspen is
Aspen’s response to the reported Competition Commission investigation
Durban – Media reports that the Competition Commission has decided to take up the Democratic Alliance’s request to investigate the alleged anti-competitive conduct of Aspen
Statement in response to press reports of 14 and 15 April 2017
In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments:
Media Enquiries
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
